HUP0102492A2 - Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására - Google Patents

Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására

Info

Publication number
HUP0102492A2
HUP0102492A2 HU0102492A HUP0102492A HUP0102492A2 HU P0102492 A2 HUP0102492 A2 HU P0102492A2 HU 0102492 A HU0102492 A HU 0102492A HU P0102492 A HUP0102492 A HU P0102492A HU P0102492 A2 HUP0102492 A2 HU P0102492A2
Authority
HU
Hungary
Prior art keywords
inhibitors
indanone
amino
transcription factor
pharmaceutical compositions
Prior art date
Application number
HU0102492A
Other languages
English (en)
Inventor
James F. Callahan
Marie C. Chabot-Fletcher
Original Assignee
Smithkline Beecham Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp. filed Critical Smithkline Beecham Corp.
Publication of HUP0102492A2 publication Critical patent/HUP0102492A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)

Abstract

A találmány NF-KB transzkripciós faktor inhibitorok, közelebbről az(I) általános képletű amino-indanon inhibitorok alkalmazásáravonatkozik, amelyek képletében R1 jelentése arilcsoport; R2 jelentésehidrogénatom, 1-6 szénatomos alkilcsoport vagy arilcsoport; R3jelentése 1-6 szénatomos alkilcsoport vagy 3-8 szénatomoscikloalkilcsoport: valamint R2 és R3 egymáshoz kapcsolódva egy 5-7atomos heterociklusos gyűrűt képezhet, amely gyűrű atomjai a következőatomok közül kerülnek kiválasztásra: szén-, nitrogén-, oxigén- éskénatom. Ó
HU0102492A 1998-06-19 1998-06-18 Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására HUP0102492A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9001698P 1998-06-19 1998-06-19
PCT/US1999/013897 WO1999065495A1 (en) 1998-06-19 1999-06-18 INHIBITORS OF TRANSCRIPTION FACTOR NF-λB

Publications (1)

Publication Number Publication Date
HUP0102492A2 true HUP0102492A2 (hu) 2001-11-28

Family

ID=22220761

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102492A HUP0102492A2 (hu) 1998-06-19 1998-06-18 Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására

Country Status (17)

Country Link
EP (1) EP1085872A4 (hu)
JP (1) JP2002518333A (hu)
KR (1) KR20010052990A (hu)
CN (1) CN1306428A (hu)
AR (1) AR019871A1 (hu)
AU (1) AU4699699A (hu)
BR (1) BR9911151A (hu)
CA (1) CA2335293A1 (hu)
CO (1) CO5080752A1 (hu)
CZ (1) CZ20004760A3 (hu)
HU (1) HUP0102492A2 (hu)
IL (1) IL140324A0 (hu)
NO (1) NO20006452L (hu)
PL (1) PL345577A1 (hu)
TR (1) TR200003779T2 (hu)
WO (1) WO1999065495A1 (hu)
ZA (1) ZA200007448B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509431A (ja) 1996-12-23 2002-03-26 イミュネックス・コーポレーション ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP2009025B1 (en) 1998-05-14 2011-07-27 Immunex Corporation Method of inhibiting osteoclast activity
DE60129926T2 (de) * 2000-01-24 2008-06-19 Genzyme Corp., Cambridge Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
US7812018B2 (en) 2006-02-16 2010-10-12 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
EP2366699B1 (en) 2008-10-02 2013-08-07 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and use thereof
US9127016B2 (en) 2009-03-20 2015-09-08 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of Dusp6 and uses therefor
EP2461806A4 (en) * 2009-07-31 2012-12-26 Us Health SMALL ANTI-ANGIOGENIC MOLECULES AND METHODS OF USE
US10160705B2 (en) 2011-02-10 2018-12-25 University of Pittsburgh—of the Commonwealth System of Higher Education Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury
WO2014071000A1 (en) 2012-10-31 2014-05-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Class of hdac inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury

Also Published As

Publication number Publication date
EP1085872A4 (en) 2003-04-16
AR019871A1 (es) 2002-03-20
IL140324A0 (en) 2002-02-10
JP2002518333A (ja) 2002-06-25
ZA200007448B (en) 2001-12-12
NO20006452D0 (no) 2000-12-18
EP1085872A1 (en) 2001-03-28
CA2335293A1 (en) 1999-12-23
PL345577A1 (en) 2001-12-17
CZ20004760A3 (cs) 2001-08-15
WO1999065495A1 (en) 1999-12-23
CN1306428A (zh) 2001-08-01
TR200003779T2 (tr) 2001-06-21
BR9911151A (pt) 2001-03-06
CO5080752A1 (es) 2001-09-25
KR20010052990A (ko) 2001-06-25
AU4699699A (en) 2000-01-05
NO20006452L (no) 2001-02-16

Similar Documents

Publication Publication Date Title
HUP0300743A2 (hu) Heteroarilszármazékok és alkalmazásuk gyógyszerként
HUP0300782A2 (hu) Nitrogéntartalmú heterociklusos kaszpáz inhibitorok, eljárás az elżállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0302997A2 (hu) alfa4-Integrin antagonista hatású fenilalanin-származékok, azokat tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0102492A2 (hu) Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
HUP0300138A2 (en) Cyclic amine derivatives as ccr5 antagonists, their production and use and pharmaceutical compositions containing them
HUP0302468A2 (hu) Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
HUP0105142A2 (hu) 4-oxo-1,4-dihidro-3-kinolin-karboxamid-származékok, mint vírusellenes hatóanyagok és ezeket tartalmazó gyógyszerkészítmények
HUP0300205A2 (en) Aurora 2 kinase inhibitor quinazoline derivatives, preparation and use thereof
HUP0002848A2 (hu) Ciklobuténszármazékok, eljárás előállításukra és terápiás alkalmazásuk
HUP9900006A2 (hu) Ciklikus GMP-specifikus foszfo-diészteráz inhibitor vegyületek, előállításuk és ezeket tartalmazó gyógyszerkészítmények
CA2078759A1 (en) Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0204399A2 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0100669A2 (hu) Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0001848A2 (hu) NOS gátló 6-fenil-piridil-2-amin származékok
HUP0203206A2 (hu) Eljárás 4-trifluormetilszulfinilpirazol-származékok előállítására
HUP0000942A2 (hu) Kinolin- és kinazolinszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek előállítása és alkalmazása
HUP9600071A2 (hu) Indolil-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
DE3876813D1 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
CA2203237A1 (en) Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
HUP9801946A2 (hu) 5-HT-felvétel-inhibitorból és szelektív 5-H1A-antagonistából álló kombinációs gyógyászati készítmény és eljárás előállítására
HU914092D0 (en) Process for producing cyclic compounds containing amino or nitro group and acting as enzyme inhibitor
HUP0105105A2 (hu) Gyulladásgátló hatású makrolidok és ezeket tartalmazó gyógyszerkészítmények
HUP0003760A2 (hu) Metalloproteináz és TNF-felszabadulás inhibitor hatású tio-szubsztituált peptidek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk